$13.13
0.23% today
Nasdaq, Feb 05, 07:50 pm CET
ISIN
US03969K1088
Symbol
ARQT
Sector
Industry

Arcutis Biotherapeutics Inc Target price 2025 - Analyst rating & recommendation

Arcutis Biotherapeutics Inc Classifications & Recommendation:

Buy
88%
Hold
13%

Arcutis Biotherapeutics Inc Price Target

Target Price $19.50
Price $13.10
Potential
Number of Estimates 8
8 Analysts have issued a price target Arcutis Biotherapeutics Inc 2026 . The average Arcutis Biotherapeutics Inc target price is $19.50. This is higher than the current stock price. The highest price target is , the lowest is .
A rating was issued by 8 analysts: 7 Analysts recommend Arcutis Biotherapeutics Inc to buy, 1 to hold and 0 to sell.
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
Analyst Estimates: Analysts believe that the Arcutis Biotherapeutics Inc stock has an average upside potential 2026 of . Most analysts recommend the Arcutis Biotherapeutics Inc stock at Purchase.

Sales and Margin forecast 2024, 2025 to 2028

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Dec '23 2024
Estimates
Revenue Million $ 59.61 185.46
1,515.45% 211.13%
EBITDA Margin -401.31% -80.58%
95.07% 79.92%
Net Margin -741.92% -80.43%
95.87% 89.16%

8 Analysts have issued a sales forecast Arcutis Biotherapeutics Inc 2024 . The average Arcutis Biotherapeutics Inc sales estimate is

$185m
Unlock
. This is
33.71% higher
Unlock
than the revenue of the last 12 months(TTM). The highest sales forecast is
$189m 36.04%
Unlock
, the lowest is
$179m 28.88%
Unlock
.

This results in the following potential growth metrics:

Revenue Estimates

2023 $59.6m 1,515.45%
2024
$185m 211.13%
Unlock
2025
$289m 55.64%
Unlock
2026
$423m 46.60%
Unlock
2027
$636m 50.28%
Unlock
2028
$789m 24.04%
Unlock

2 Analysts have issued an Arcutis Biotherapeutics Inc EBITDA forecast 2024. The average Arcutis Biotherapeutics Inc EBITDA estimate is

$-149m
Unlock
. This is
16.70% higher
Unlock
than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is
$-146m 18.48%
Unlock
, the lowest is
$-153m 14.91%
Unlock
.

This results in the following potential growth metrics and future EBITDA Margins:

EBITDA Estimates

2023 $-239m 20.36%
2024
$-149m 37.52%
Unlock
2025
$-119m 20.70%
Unlock
2026
$-39.4m 66.76%
Unlock

EBITDA Margin

2023 -401.31% 95.07%
2024
-80.58% 79.92%
Unlock
2025
-41.06% 49.04%
Unlock
2026
-9.31% 77.33%
Unlock

4 Arcutis Biotherapeutics Inc Analysts have issued a net profit forecast 2024. The average Arcutis Biotherapeutics Inc net profit estimate is

$-149m
Unlock
. This is
28.77% higher
Unlock
than the net profit for the last 12 months(TTM). The highest net profit forecast is
$-137m 34.64%
Unlock
, the lowest is
$-158m 24.58%
Unlock
.

This results in the following potential growth metrics and future Net Margins:

Net Profit Estimates

2023 $-442m 33.22%
2024
$-149m 66.27%
Unlock
2025
$-83.7m 43.92%
Unlock
2026
$35.1m 141.96%
Unlock
2027
$257m 633.33%
Unlock
2028
$415m 61.14%
Unlock

Net Margin

2023 -741.92% 95.87%
2024
-80.43% 89.16%
Unlock
2025
-28.98% 63.97%
Unlock
2026
8.29% 128.61%
Unlock
2027
40.48% 388.30%
Unlock
2028
52.58% 29.89%
Unlock

Earnings per share, P/E ratio and EV/sales Estimates 2024, 2025 to 2028

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Dec '23 2024
Estimates
Earnings Per Share $ -3.78 -1.28
33.22% 66.14%
P/E negative
EV/Sales 7.60

4 Analysts have issued a Arcutis Biotherapeutics Inc forecast for earnings per share. The average Arcutis Biotherapeutics Inc <a href=https://blog.stocksguide.com/knowledge/eps-simply-explained>EPS is

$-1.28
Unlock
. This is
28.49% higher
Unlock
than earnings per share in the financial year 2023. The highest <a href=https://blog.stocksguide.com/knowledge/eps-simply-explained>EPS forecast is
$-1.17 34.64%
Unlock
, the lowest is
$-1.35 24.58%
Unlock
.

This results in the following potential growth metrics and future valuations:

Earnings Per Share

2023 $-3.78 33.22%
2024
$-1.28 66.14%
Unlock
2025
$-0.72 43.75%
Unlock
2026
$0.30 141.67%
Unlock
2027
$2.20 633.33%
Unlock
2028
$3.55 61.36%
Unlock

P/E ratio

Current -7.31 583.18%
2024
-10.27 40.49%
Unlock
2025
-18.32 78.38%
Unlock
2026
43.67 338.37%
Unlock
2027
5.95 86.38%
Unlock
2028
3.70 37.82%
Unlock

Based on analysts' sales estimates for 2024, the Arcutis Biotherapeutics Inc stock is valued at an <a href=https://blog.stocksguide.com/knowledge/enterprise-value-sales-simply-explained>EV/Sales of

and an <a href=https://blog.stocksguide.com/knowledge/price-sales-ratio-simply-explained>P/S ratio of .

This results in the following potential growth metrics and future valuations:

EV/Sales

Current 10.17 93.35%
2024
7.60 25.23%
Unlock
2025
4.89 35.75%
Unlock
2026
3.33 31.79%
Unlock
2027
2.22 33.46%
Unlock
2028
1.79 19.38%
Unlock

P/S ratio

Current 11.05 93.06%
2024
8.27 25.21%
Unlock
2025
5.31 35.75%
Unlock
2026
3.62 31.79%
Unlock
2027
2.41 33.46%
Unlock
2028
1.94 19.38%
Unlock

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today